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Gadobenate Dimeglumine as an
Intrabiliary Contrast Agent: Comparison
with Mangafodipir Trisodium with Respect
to Non-dilated Biliary Tree Depiction
Objective: To compare the efficacy of Mangafodipir trisodium (Mn-DPDP)-
enhanced MR cholangiogrphy (MRC) and Gadobenate dimeglumine (Gd-
BOPTA)-enhanced MRC in visualizing a non-dilated biliary system. 
Materials and Methods: Eighty-eight healthy liver donor candidates underwent
contrast-enhanced T1-weighted MRC. Mn-DPDP and Gd-BOPTA was used in 36
and 52 patients, respectively. Two radiologists reviewed the MR images and
rated the visualization of the common duct, the right and left hepatic ducts, and
the second-order branches using a 4-point scale. The contrast-to-noise ratio
(CNR) of the common duct to the liver in the two groups was also compared.
Results: Mn-DPDP MRC and Gd-BOPTA MRC both showed similar visualiza-
tion grades in the common duct (p = .380, Mann-Whitney U test). In the case of
the proximal bile ducts, the median visualization grade was significantly higher
with Gd-BOPTA MRC than with Mn-DPDP MRC (right hepatic duct: p = 0.016,
left hepatic duct: p = 0.014, right secondary order branches: p = 0.006, left sec-
ondary order branches, p = 0.003). The common duct-to-liver CNR of the Gd-
BOPTA MRC group was significantly higher (38.90 24.50) than that of the Mn-
DPDP MRC group (24.14 17.98) (p = .003, Student’s t test).
Conclusion: Gd-BOPTA, as a biliary contrast agent, is a potential substitute for
Mn-DPDP.
urrent state of the art MR cholangiographic examination, which relies
upon the T2-weighted sequences, is highly accurate in identifying biliary
diseases (1 3). However, the T2-weighted MR cholangiography (MRC)
has diagnostic limitations which include poor visualization of the intrahepatic biliary
tree compared with the extrahepatic biliary tree (4, 5), variation in the degree of T2-
weighting that might obscure the biliary structures (6), and limited spatial resolution.
During the past few years, T1-weighted MRC using hepatocyte-directed contrast
agents has created interest in the field of MRC because of its potential to provide
functional information and to improve the visualization of the non-dilated biliary
system (7 13). Initially, mangafodipir trisodium (Mn-DPDP), which is mainly being
excreted into biliary system, has been used for this purpose (8, 9, 11 13). However,
dynamic MR imaging of the liver cannot be performed because this agent needs to be
administered slowly. Recently, contrast agents that are excreted through both the
renal and biliary pathways, such as gadobenate dimeglumine (Gd-BOPTA) have
become available (14 17). Using a bolus injection technique, these agents can be used
for dynamic imaging as an extracellular space agent in the early phase as well as a
biliary contrast agent in the delayed phase. However, because the proportion of the
amount that is excreted through the biliary system is relatively small, the scan window
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Cfor the biliary imaging should be delayed more compared
to manganese agents. To our knowledge, the relative
efficacy of these two agents in terms of ductal visualization
has not been compared directly.
The aim of this study was to investigate the feasibility of
Gd-BOPTA MRC and to compare it with Mn-DPDP MRC
in terms of the extrahepatic and intrahepatic ductal visual-
ization in patients with a normal or undilated biliary
system. 
MATERIALS AND METHODS
Eighty-eight healthy liver donor candidates underwent
contrast enhanced T1-weighted MRC. Between April 2001
and June 2003, liver donor candidates (age range, 19 54
years; mean age, 34.1 years) (21 women and 67 men)
underwent an evaluation with MR imaging. Mn-DPDP was
used as an intrabiliary T1 contrast agent in 36 patients
between April 2001 and April 2002, and Gd-BOPTA was
used in 52 patients between May 2002 and June 2003.
None of the subjects had known or suspected biliary
abnormalities at the time of the examination. Our institu-
tional review board approved all aspects of this retrospec-
tive study and did not require informed consent from any
patients whose records were included in our study. 
MR Imaging Technique
Both Mn-DPDP MRC and Gd-BOPTA MRC examina-
tions were performed with a 1.5-T imaging system, using a
torso phased array coil at one of the two MR systems.
(Horizon, GE Medical Systems, Milwaukee, WI; Philips
Medical Systems, Best, the Netherlands). Thirty five Mn-
DPDP MRC examinations were performed using the
former and one Mn-DPDP MRC examination and all Gd-
BOPTA MRC examinations were performed using the
latter.
Mn-DPDP MRC was obtained following an IV injection
of mangafodipir trisodium (Teslascan; Nycomed,
Princeton, NJ) at the standard dose of 5  mol/kg (0.5
mL/kg) administered via a slow injection for 1 2 min
followed by a 10-mL saline flush. Fifteen to 30 min after
the injection, axial and coronal volumetric 3D spoiled
gradient-echo acquisitions of the liver and biliary system
were performed, using the following parameters: TR
range/TE, 5 8/minimum; flip angle, 20°; matrix, 256
160; field of view, 34 cm using a rectangular field of view;
and 4 mm slice thickness with a 2-mm reconstruction
interval. In the case of Gd-BOPTA MRC, three-
dimensional (3D) breath-hold T1-weighted fast-field-echo
acquisitions were performed 60 90 minutes after the
intravenous administration of the Gd-BOPTA (Multihance,
Bracco, Milan) at a dose of 0.2 mmol/kg of body weight.
The contrast agent was infused using an automated injector
for 12 seconds at a volume-adjusted rate ranging between
2.5 and 3.5 mL/s. The axial and coronal images were
obtained using the following parameters: TR range/TE,
5.1/1.47; flip angle, 40°; matrix, 512 160; field of view,
34 cm using a rectangular field of view; and a 2 mm slice
thickness with a 1-mm reconstruction interval. 
Qualitative and Semiquantitative Image Analysis
Two experienced gastrointestinal radiologists analyzed
the images retrospectively. They independently reviewed
the Mn-DPDP MRC images and Gd-BOPTA MRC images
randomly. Each observer recorded visualization grades of
the biliary tree, based on a four-point confidence rating
scale, with one representing no visualization and four
representing excellent visualization. The following
structures were evaluated: the common duct, the right and
left hepatic ducts, and the right and left second-order
division of the intrahepatic ductal branches. For the
semiquantitative analysis, one radiologist performed the
operator-defined region-of-interest (ROI) measurements of
the mean signal intensity of the common duct, the hepatic
parenchyma, and the background noise on the coronal 3D
spoiled gradient-echo image of the Mn-DPDP MRC images
and Gd-BOPTA-MRC images, using a local picture archiv-
ing and communication system (PACS) monitor and
Digital Imaging and Communications in Medicine
(DICOM) image viewing software  -view version 4.0.1.1;
Mediface, Seoul). In order to measure the common duct
signal intensity, either circular or ovoid ROIs were drawn
to encompass as much of the common duct as possible. For
the hepatic parenchyma, the ROIs were set in the area that
is devoid of focal changes in signal intensity, large vessels,
and prominent artifacts at the same level. The noise was
measured on each image using the ROIs positioned just
lateral to the abdominal wall. The areas with the most
prominent ghost artifacts were not included. The signal-to-
noise ratio (SNR) of the common duct and liver was
calculated by SIcommon duct/Nsd and SIliver/Nsd, respectively,
where the SIcommon duct and SIliver are the signal
intensities of the common duct and the liver, respectively,
and the Nsd is the standard deviation of the noise. The
contrast-to-noise ratio (CNR) between common duct and
liver was calculated by (SIcommon duct  SIliver)/Nsd. 
Statistical Analysis
The Mann-Whitney U test was used to compare the
subjective ratings of the visualization of each segment of
the biliary tree between the Mn-DPDP and Gd-BOPTA
MRC groups. The mean of the visualization grades for the
Lim et al.
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The weighted kappa ( ) test was used to measure the
interobserver agreement in the ductal visualization. The
degrees of agreement were categorized as follows:  value
of 0.00 0.20, poor agreement;  of 0.21 0.40, fair
agreement;  of 0.41 0.60, moderate agreement;  of 0.61
0.80, good agreement; and  of 0.81 1.00, excellent
agreement. The student’s t test was used to examine the
statistical significance in the differences between the SNRs
and CNRs of the two methods. A p value < 0.05 was
considered statistically significant. 
RESULTS
The median visualization grades for the qualitative
analysis are shown in Table 1. Mn-DPDP MRC and Gd-
BOPTA MRC groups both showed similar visualization
grades in the common duct (p = .380, Mann-Whitney U
test). In the case of the proximal bile ducts, the median
visualization grade was significantly higher in the Gd-
BOPTA MRC group than in the Mn-DPDP MRC group
(right hepatic duct: p = 0.016, left hepatic duct: p = 0.014,
right secondary order branches: p = 0.006, left secondary
order branches, p = 0.003) (Figs. 1, 2). The reviewers’
agreement for the degree of ductal visualization was fair to
moderate (Table 2).
Semiquantitative analysis showed that the mean SNR of
the common duct and the liver were 69.92 32.34 and
45.78 19.57 for Mn-DPDP MRC, 93.65 34.00 and
54.75 21.83 for Gd-BOPTA MRC, respectively. The
mean common duct-to-liver CNR was 24.14 17.98 for
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Table 1. Median Visualization Grades According to the
Qualitative Analysis
Structure Mn-DPDP MRC  Gd-BOPTA MRC
Common duct 4.0 4.0
Right hepatic duct* 3.5 4.0
Left hepatic duct* 4.0 4.0
Right second-order bile ducts* 2.5 3.0
Left second-order bile ducts* 2.0 2.8
Note. *Statistically significant (p < 0.05)
Fig. 1. Mn-DPDP MRC serial images
from the anterior to posterior (A D)
(TR/TE, 5.1/1.47; flip angle, 20°; 4 mm
slice thickness) shows a left lateral and
medial segment duct (short black arrow
and long black arrow in A), right and left
hepatic duct (short white arrow and
black arrow in B), common duct (long
white arrow in B), right anterior segmen-
tal duct (white arrow in C) and right
posterior segmental duct (white arrow in
D). 
AB
CDthe Mn-DPDP MRC group and 38.90 24.50 for the Gd-
BOPTA MRC group. The mean SNR of the common duct
and the common duct-to-liver CNR were significantly
higher in the Gd-BOPTA MRC group than in the Mn-
DPDP MRC group (p = .002 and p = .003, respectively,
Student’s t test).
DISCUSSION
Mn-DPDP is the first clinically available hepatocyte-
directed agent that is mostly eliminated through the biliary
system and enhances the liver signal intensity on T1-
weighted images (18 20). Approximately 50 60% of the
injected dose was found in the feces, and approximately
15 20% was found in the urine (21). Several reports have
confirmed its efficacy as a biliary contrast agent (8, 9, 11,
13). Recently, Lee et al. and Kapoor et al. (9, 11) suggested
that Mn-DPDP MRC may facilitate the definition of the
intrahepatic bile duct anatomy in healthy liver transplant
donor candidates. However, this agent cannot be used for
dynamic imaging, which is important in evaluating the
vascular anatomy and characterizing focal hepatic lesions.
Gd-BOPTA can be used as a conventional extracellular
agent for dynamic MR imaging as well as a hepatocyte-
directed agent producing a prolonged enhancement of the
liver. A pharmacokinetic study showed that approximately
2 4% of the injected dose is taken up into the functioning
hepatocytes and is eliminated through the biliary system
(17). Because of this property, Gd-BOPTA has the
potential to be a biliary contrast agent. However, to the
best of our knowledge, the clinical utility of Gd-BOPTA as
a biliary contrast agent has not been evaluated. 
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Fig. 2. Gd-BOPTA MRC serial images
from the anterior to posterior (A D)
(TR/TE, 5.1/1.47; flip angle, 40°; 2 mm
slice thickness) shows a left lateral and
medial segment duct (short black arrow
and long black arrow in A), right and left
hepatic duct (white arrow and black
arrow in B), right anterior segmental
duct (white arrow in C), right posterior
segmental duct (short white arrow in D)




Table 2. Inter-observer Agreement According to Kappa
Analysis
Structure Mn-DPDP MRC Gd-BOPTA MRC
Common duct 0.550 0.658
Right hepatic duct 0.431 0.252
Left hepatic duct 0.293 0.404
Right second-order bile ducts 0.393 0.425
Left second-order bile ducts 0.349 0.242This study showed that Gd-BOPTA MRC could be used
for anatomic assessments of non-dilated biliary trees and
was comparable or superior to Mn-DPDP in terms of the
ductal visualization. This is an intriguing result because the
proportion of Gd-BOPTA excreted into the biliary system
is substantially lower than Mn-DPDP (21). The relaxivity
of Gd-BOPTA is higher than that of Mn-DPDP in liver
tissue (30 vs. 21.7 [mmol
1 S
1]) (22). Macromolecular
binding, with the resultant increase in relaxivity, may
compensate for the lower hepatocellular uptake of Gd-
BOPTA compared to that of Mn-DPDP.
There were some limitations to this study. First, because
our study was a retrospective study, a direct comparison of
both contrast agents in the same patient was not
performed. In addition, the depiction of the biliary tree on
the contrast enhanced MRC may show a different result
based on the liver function regardless of the administered
contrast agents. However, this study included only healthy
liver donor candidates with normal functioning livers.
Second, the Mn-DPDP-enhanced and the Gd-BOPTA-
enhanced MRC were obtained approximately between 15
minutes to 30 minutes, and between 60 minutes to 90
minutes, respectively, after injecting the contrast media.
Since we did not obtain serial images from both the Mn-
DPDP and Gd-BOPTA MRC, we are not sure whether the
delayed images provided best scan window for the biliary
tree depiction. However, it was reported that the optimal
window for evaluating the liver parenchyma and the bile
duct after injection, range from 15 to 20 minutes for Mn-
DPDP MRC (7, 9, 13) and 60 to 120 minutes for Gd-
BOPTA MRC (23). Third, the MR scanners and the pulse
sequence parameters were not the same in the two differ-
ent contrast-enhanced techniques. Most of the Gd-BOPTA-
enhanced MRC was performed using a newer version of
the MR system which uses a thinner section thickness. This
was because the new MR system was installed during this
study. Therefore, the superior results of Gd-BOPTA MRC
for intrahepatic duct visualization may be due in part to
the more optimized scan parameters. However, our results
showed that the Gd-BOPTA-enhanced MRC obtained with
updated MR system are comparable to MnDPDP-enhanced
MRC obtained by the less updated MR system.
In conclusion, although a fair comparison between the
two contrast agents for ductal visualization could not be
performed due to the limitations of the study, the data
suggest that Gd-BOPTA MRC is comparable to Mn-DPDP
MRC in visualizing the biliary duct in either a normal or
non-dilated biliary system. Therefore, Gd-BOPTA, as a
biliary contrast agent, is a potential substitute for Mn-
DPDP.
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